Healthcare / BiotechnologyKOSDAQ
$2110.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-8.9B · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$28.1B
P/E
N/A
•EV/EBITDA
5.6x
↓ROE
-2.1%
↓Gross Margin
15.8%
↓Debt/Equity
2.78
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.9%
FCF CAGR
—
FCF margin
-11.6%
FCF / Net income
28.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $76.19B · net income $-315.6M · FCF $-8.87B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $76.19B | $76.19B | $57.70B | $42.88B | $45.29B |
| Net Income | $-315.6M | $-315.6M | $-80.36B | $-1.96B | $-12.02B |
| EBITDA | $9.31B | $9.31B | $-55.42B | $-985.0M | $-10.41B |
| EPS | -122.00 | -122.00 | -59984.00 | -320.00 | -2200.00 |
| Gross Margin | 15.8% | 15.8% | 8.9% | 12.4% | 15.0% |
| Operating Margin | -5.6% | -5.6% | -6.7% | -4.4% | -9.0% |
| Net Margin | -0.4% | -0.4% | -139.3% | -4.6% | -26.6% |
| Balance Sheet | |||||
| Debt/Equity | 2.78 | 2.78 | 1.22 | 0.15 | 0.15 |
| Current Ratio | 1.81 | 1.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.87B | $-8.87B | $-9.63B | $-2.50B | $-4.25B |
| Returns | |||||
| ROE | -2.1% | -2.1% | -459.5% | -5.3% | -38.7% |
| Valuation | |||||
| EV/EBITDA | 5.65 | 5.65 | — | — | — |
| P/B | 1.83 | 1.83 | 0.75 | 1.45 | 1.76 |
| Growth & Yield | |||||
| Revenue Growth | 32.0% | 32.0% | 34.5% | -5.3% | — |
| EPS Growth | 99.8% | 99.8% | -18645.0% | 85.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-59984.00 → -122.00
Residual
+21.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.